Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
about
Synergistic antifungal effect of glabridin and fluconazolePd@Ag Nanosheets in Combination with Amphotericin B Exert a Potent Anti-Cryptococcal Fungicidal EffectFungal biofilms and drug resistance.Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosisRecommendations for the treatment of fungal pneumonias.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Anidulafungin: an echinocandin antifungal.Combination treatment of invasive fungal infections.Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indolesCaspofungin: an overview.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.Antifungal activity of Cymbopogon winterianus jowitt ex bor against Candida albicansAnidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.Echinocandin pharmacodynamics: review and clinical implications.Candida tropicalis in human disease.In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsSynergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.Chemosensitization as a means to augment commercial antifungal agents.In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis.Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
P2860
Q28541182-B950C32E-27F3-424A-9F96-8307797AECC9Q28550084-1DD57BAC-E177-4E32-BE26-3674F22E5EC2Q34540389-1FE8773C-70F0-4BE7-89DF-BE89A776F83FQ34576400-E5C52D63-366D-4EDE-92DF-EBFD973C548CQ34737783-3F8F4AEE-FA4A-4C60-9062-5D3264EE6BECQ35183728-EB8C5F81-7046-4294-9A7C-0C8319048430Q35185757-96B347B7-8D32-4550-BD63-0D7750B34684Q35738800-D8FF6316-74CD-4665-972D-6DB49F38FBD8Q35871936-12A4EE91-4CA1-411D-B428-49318D86F6DDQ36011378-306633AF-64F7-4187-B84B-41649070A86CQ36068254-372D595E-D735-4430-AB15-69DFE356098FQ36278031-807CCBC0-796D-4579-8E91-4C2B88815087Q36441524-934573CE-551A-4CD6-8121-B723B24B38F2Q36458402-D11853FD-2736-425D-8E3C-E57B426AB4F4Q36538716-10057071-F92E-41D2-A65A-F18DED3904F6Q37162258-C37E9A2E-425E-4A79-B04D-75AA346FBB3AQ37274747-B1C2F0C7-321C-440C-80C0-9E4943202E16Q37718385-A55C437A-3FAC-4EEF-B9C4-CE3D18EC25E5Q37794979-CCC88F35-6FBA-4507-B103-69840A55C885Q39077602-B58BEE77-A185-48D0-9BAB-106E2858B677Q39701953-4C2E1D92-ED3D-4C87-9CF2-2AC4C389650EQ41442442-105A403D-9461-4F76-89EC-6FC652A87E59Q41772012-4EB8379F-A4BE-4C95-9442-28D4A3A17095Q41835779-2D6177E4-ECDE-4953-829D-A7BDD2CCA557Q42104395-F22E05C9-19E3-4442-93EF-100BDD74DF75Q42110115-548982B2-3071-459D-8943-21E42D3D504AQ42111638-237F4D2C-F580-4873-9140-F89F694D2D03Q42141903-FCA1C913-0139-4562-96D1-DE60F4E469F3Q42845954-189511B5-7DF5-4222-B35A-DE8C30AF5C97Q44445840-6D92E82A-3FAF-480E-A91B-C197891408CEQ47434555-7FEEF144-1FA2-43C6-808F-66F69DE34984
P2860
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Antifungal activities of fluco ...... formans via time-kill methods.
@en
Antifungal activities of fluco ...... formans via time-kill methods.
@nl
type
label
Antifungal activities of fluco ...... formans via time-kill methods.
@en
Antifungal activities of fluco ...... formans via time-kill methods.
@nl
prefLabel
Antifungal activities of fluco ...... formans via time-kill methods.
@en
Antifungal activities of fluco ...... formans via time-kill methods.
@nl
P2093
P1476
Antifungal activities of fluco ...... formans via time-kill methods.
@en
P2093
Ashley Wasson
Ellen E Roling
Erika J Ernst
Michael E Klepser
P356
10.1016/S0732-8893(02)00361-9
P577
2002-05-01T00:00:00Z